More Checks And Balances For Orphan Drugs Needed, Says Germany’s G-BA

The German pricing and reimbursement authority wants better scrutiny of orphan drug designations and incentives for orphan drug development to help address the access problem.

formula

There should be more “checks and balances” on incentives for companies developing orphan drugs and the criteria for determining EU orphan status, says the G-BA, Germany’s federal health insurance and reimbursement authority.

The high prices that companies often charge thanks to their orphan status mean that many rare disease patients in Europe...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Rare Diseases

More from Pink Sheet